Using probiotics to improve treatment for triple-negative breast cancer
Modulation of the tumor microenvironment with probiotic therapies
['FUNDING_R01'] · COLUMBIA UNIV NEW YORK MORNINGSIDE · NIH-10814915
This study is looking at how specially designed probiotic bacteria can help boost cancer treatment for people with triple-negative breast cancer by targeting tumors and releasing helpful substances right where they're needed, aiming to make the treatment more effective and with fewer side effects.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | COLUMBIA UNIV NEW YORK MORNINGSIDE (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-10814915 on ClinicalTrials.gov |
What this research studies
This research investigates how engineered probiotic bacteria can be used to enhance immunotherapy for patients with triple-negative breast cancer (TNBC). The approach involves creating specific strains of probiotics that can target and colonize breast tumors, releasing therapeutic agents directly within the tumor environment. By doing so, the goal is to stimulate a stronger immune response against the cancer while minimizing side effects associated with traditional therapies. The study will explore the mechanisms that allow these probiotics to thrive in tumor settings and how they can be modified to improve their effectiveness.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer who are seeking innovative treatment options.
Not a fit: Patients with other types of breast cancer or those who are not eligible for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with triple-negative breast cancer.
How similar studies have performed: Other research has shown promise in using probiotics for cancer treatment, but this specific approach of engineering probiotics for targeted immunotherapy is relatively novel.
Where this research is happening
NEW YORK, UNITED STATES
- COLUMBIA UNIV NEW YORK MORNINGSIDE — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DANINO, TAL — COLUMBIA UNIV NEW YORK MORNINGSIDE
- Study coordinator: DANINO, TAL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.